Table 1 In vitro efficacy (Emax), inhibitory concentration required to kill 90% of bacteria (IC90), safety (LD50) and selectivity index (SI; ratio of IC90 to LD50) of Stm hit compounds against intracellular Stm.
From: Identification of kinase inhibitors as potential host-directed therapies for intracellular bacteria
Compound | Emax (% inh.) | IC90 (μM) | LD50 (µM) | SI |
|---|---|---|---|---|
GSK1379738A | 100 (92–100) | 5.5 (3.9–9.2) | 450 (34–116) | 8.2 |
GSK1379760A | 100 (93–100) | 5.8 (3.8–9.9) | 161 (ND) | 28 |
GSK507358A | 100 (87–100) | 14.3 (9.7-ND) | 490 (ND-156) | 3.4 |
GW284543A | 098 (85–100) | 7.2 (4.5-ND) | 240 (21–27) | 3.3 |
GW412617A | 099 (91–100) | 2.2 (1.4–4.7) | 330 (28–50) | 15 |
GW560116X | 099 (90–100) | 1.8 (1.3–3.2) | ND | ND |
SB-284851-BT | 100 (93–100) | 7.6 (5.3–12.5) | 260 (22–32) | 3.4 |
